The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience.
 
Arjun Gupta
No Relationships to Disclose
 
Omar Khalid
Other Relationship - Abbvie (Inst); Allergan Foundation (Inst); Amgen Foundation (Inst); AngioDynamics (Inst); AstraZeneca (Inst); Baxter International Foundation (Inst); Boston Biomedical (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Elstar Therapeutics (Inst); ERYTECH Pharma (Inst); Genentech (Inst); GlaxoSmithKline Foundation (Inst); Halozyme (Inst); Immunovia (Inst); Interpace Diagnostics (Inst); Ipsen (Inst); Janssen Research & Development (Inst); Johnson & Johnson (Inst); Lilly (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); SERVIER (Inst); Shire (Inst); Takeda (Inst); TriSalus Life Sciences (Inst); TYME (Inst)
 
Dennis Ladnier
No Relationships to Disclose
 
Cassadie Moravek
Consulting or Advisory Role - AstraZeneca
Other Relationship - Abbvie (Inst); Allergan Foundation (Inst); Amgen Foundation (Inst); AngioDynamics (Inst); AstraZeneca (Inst); Baxter International Foundation (Inst); Boston Biomedical (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Elstar Therapeutics (Inst); ERYTECH Pharma (Inst); Genentech (Inst); GlaxoSmithKline Foundation (Inst); Halozyme (Inst); Immunovia (Inst); Interpace Diagnostics (Inst); Ipsen (Inst); Janssen Research & Development (Inst); Johnson & Johnson (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck Sharp & Dohme (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); SERVIER (Inst); Shire (Inst); Takeda (Inst); TriSalus Life Sciences (Inst); TYME (Inst)
 
Anica Lamkin
No Relationships to Disclose
 
Lynn McCormick Matrisian
Other Relationship - Abbvie (Inst); Allergan Foundation (Inst); Amgen Foundation (Inst); AngioDynamics (Inst); AstraZeneca (Inst); Baxter (Inst); Boston Biomedical (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Elstar Therapeutics (Inst); ERYTECH Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunovia (Inst); Interpace Diagnostics (Inst); Ipsen (Inst); Janssen Research & Development (Inst); Johnson & Johnson (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck Sharp & Dohme (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); SERVIER (Inst); Shire (Inst); Takeda (Inst); TriSalus Life Sciences (Inst); TYME (Inst)
 
Sudheer Doss
Stock and Other Ownership Interests - Exact Sciences
 
Crystal S. Denlinger
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Lilly; Merck; Taiho Pharmaceutical
Research Funding - Agios (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genmab (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Merrimack (Inst); Sanofi (Inst); Zymeworks (Inst)
 
Andrew L. Coveler
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen
Research Funding - AbGenomics International (Inst); Amgen (Inst); Amgen (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novocure (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Halozyme
 
Colin D. Weekes
Honoraria - Bayer; Celgene; Lilly; Merrimack
Consulting or Advisory Role - Celgene; Ipsen; Merrimack
Research Funding - Abbvie; AstraZeneca; Bayer; Celgene; Genentech/Roche; Gilead Sciences; Halozyme; Ipsen; Lilly; Millennium
Travel, Accommodations, Expenses - Bayer; Celgene; Lilly
 
Eric Roeland
Consulting or Advisory Role - AIM Specialty Health; Asahi Kasei; BASF; HERON; Immuneering; Mitobridge; Napo Pharmaceuticals; Oragenics; Oragenics; Pfizer/EMD Serono; Vector Oncology
Expert Testimony - Regents of the University of California
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Celgene; Ipsen; Novartis; Perthera
Research Funding - Ipsen
Travel, Accommodations, Expenses - Halozyme
 
Ryan David Nipp
No Relationships to Disclose